SCHEMBL22276366

SCHEMBL22276366

CCNC(=O)C1CCCCCC(CC)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.58
NAAA Q02083 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CYP3A4 P08684 1/20 0.44
RAB9A P51151 1/20 0.44
OPRM1 P35372 1/20 0.43
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
CTSK P43235 1/20 0.43
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
BCHE P06276 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15200265 0.91 OPRM1 (0.48) EPHX1NAAASMN1; SMN2HSD17B10CYP3A4
SCHEMBL687030 0.91 OPRM1 (0.48) EPHX1NAAASMN1; SMN2HSD17B10CYP3A4
SCHEMBL15580639 0.91 OPRM1 (0.48) EPHX1NAAASMN1; SMN2HSD17B10CYP3A4
SCHEMBL61528 0.87 NAAA (0.61) EPHX1NAAASMN1; SMN2HSD17B10CYP3A4
SCHEMBL19669659 0.87 NAAA (0.61) EPHX1NAAASMN1; SMN2HSD17B10CYP3A4
SCHEMBL7484827 0.87 NAAA (0.61) EPHX1NAAASMN1; SMN2HSD17B10CYP3A4
SCHEMBL1810307 0.85 SMN1; SMN2 (0.61) EPHX1NAAASMN1; SMN2HSD17B10CYP3A4
SCHEMBL1768082 0.81
SCHEMBL1678458 0.81
SCHEMBL17723434 0.81 EPHX1 (0.46) EPHX1NAAASMN1; SMN2HSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200239435-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2020-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239435-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 EPHX1 451/4885NAAA 658/4885SMN1; SMN2 4577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.